Testing Treatment for Prostate Cancer
common.study.values.description
“Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer”
Patients with hormone sensitive oligometastatic prostate cancer (a?$ 5 metastatic tumours outside of regional pelvic nodes with no more than 3 in any organ system) and no previous treatment to prostate will be treated with intermittent androgen deprivation therapy +/- chemotherapy, stereotactic radiotherapy to all metastases, and either radical prostatectomy or radiotherapy.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods


Procedure - Radical prostatectomy
Radical prostatectomy
Radiation - HDR (19Gy) or SBRT (35-40Gy)
Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
participant.views.study.view.additional
participant.views.study.view.scientific-title
Randomized Feasibility Trial of Prostate Radiotherapy vs Prostatectomy in Men With Hormone Sensitive Oligometastatic Prostate Cancer
common.study.values.clinical-trial-id
NCT03301701
participant.views.study.view.id
QeZ1vd